{
    "id": "e69d1c61a4",
    "abstract": [],
    "body_text": [
        {
            "text": "A cute decompensated heart failure (ADHF) is one of the leading causes of hospitalization. "
        },
        {
            "text": "More than 30% of patients hospitalized for ADHF experience acute kidney injury (AKI), [1][2][3][4][5][6][7][8] which is independently associated with increased risk of morbidity and mortality. ",
            "ref_spans": [
                {
                    "start": 86,
                    "end": 89,
                    "type": "bibr",
                    "text": "[1]"
                },
                {
                    "start": 89,
                    "end": 92,
                    "type": "bibr",
                    "text": "[2]"
                },
                {
                    "start": 92,
                    "end": 95,
                    "type": "bibr",
                    "text": "[3]"
                },
                {
                    "start": 95,
                    "end": 98,
                    "type": "bibr",
                    "text": "[4]"
                },
                {
                    "start": 98,
                    "end": 101,
                    "type": "bibr",
                    "text": "[5]"
                },
                {
                    "start": 101,
                    "end": 104,
                    "type": "bibr",
                    "text": "[6]"
                },
                {
                    "start": 104,
                    "end": 107,
                    "type": "bibr",
                    "text": "[7]"
                },
                {
                    "start": 107,
                    "end": 110,
                    "type": "bibr",
                    "text": "[8]"
                }
            ]
        },
        {
            "text": "9,10 The clinical importance of the coexistence of acute cardiac and renal dysfunction, known as acute cardiorenal syndrome (CRS), and its management have received great attention recently. ",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "9,"
                },
                {
                    "start": 2,
                    "end": 4,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "10"
                }
            ]
        },
        {
            "text": "[11][12][13] The poor prognosis of acute CRS makes the identification of patients at high risk especially important. ",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 4,
                    "type": "bibr",
                    "ref_id": "b11",
                    "text": "[11]"
                },
                {
                    "start": 4,
                    "end": 8,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "[12]"
                },
                {
                    "start": 8,
                    "end": 12,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "[13]"
                }
            ]
        },
        {
            "text": "However, early diagnosis of acute CRS has remained elusive due to restrictions on using serum creatinine or urine output for diagnosis of AKI. "
        },
        {
            "text": "14 The current diagnostic paradigm for AKI relies largely on biomarkers of renal function (serum creatinine and urine output) that have been in clinical use for over 50 years but are known to be insensitive and slow to change after kidney injury, often leading to a late and inaccurate diagnosis of AKI with resultant adverse outcomes. ",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b14",
                    "text": "14"
                }
            ]
        },
        {
            "text": "9,10,14 Therefore, the current paradigm of AKI diagnosis needs to be reassessed in light of scientific advances in the understanding of the pathobiology of AKI facilitated in part by recent biomarker discovery programs. ",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "9,"
                },
                {
                    "start": 2,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "10,"
                },
                {
                    "start": 5,
                    "end": 7,
                    "type": "bibr",
                    "ref_id": "b14",
                    "text": "14"
                }
            ]
        },
        {
            "text": "15 Although it has been the goal of several studies to develop kidney injury biomarkers (such as neutrophil gelatinaseassociated lipocalin [NGAL] and urinary angiotensionogen [uAGT]) 13,[16][17][18][19][20][21][22] for early detection of AKI before occurrence of renal dysfunction, these studies have yielded varied performance. ",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b15",
                    "text": "15"
                },
                {
                    "start": 139,
                    "end": 145,
                    "type": "bibr",
                    "text": "[NGAL]"
                },
                {
                    "start": 183,
                    "end": 186,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "13,"
                },
                {
                    "start": 186,
                    "end": 190,
                    "type": "bibr",
                    "ref_id": "b16",
                    "text": "[16]"
                },
                {
                    "start": 190,
                    "end": 194,
                    "type": "bibr",
                    "ref_id": "b17",
                    "text": "[17]"
                },
                {
                    "start": 194,
                    "end": 198,
                    "type": "bibr",
                    "ref_id": "b18",
                    "text": "[18]"
                },
                {
                    "start": 198,
                    "end": 202,
                    "type": "bibr",
                    "ref_id": "b19",
                    "text": "[19]"
                },
                {
                    "start": 202,
                    "end": 206,
                    "type": "bibr",
                    "ref_id": "b20",
                    "text": "[20]"
                },
                {
                    "start": 206,
                    "end": 210,
                    "type": "bibr",
                    "ref_id": "b21",
                    "text": "[21]"
                },
                {
                    "start": 210,
                    "end": 214,
                    "type": "bibr",
                    "ref_id": "b22",
                    "text": "[22]"
                }
            ]
        },
        {
            "text": "This suggests that a single biomarker (or single type of biomarkers) is not sufficient for the evaluation of clinical settings such as CRS. "
        },
        {
            "text": "15,17 Therefore, reformulating the predictive approach of AKI, ie, a multimarker approach, is more likely to be of greater use. ",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b15",
                    "text": "15,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b17",
                    "text": "17"
                }
            ]
        },
        {
            "text": "23 The major purpose of our study is to incorporate both clinical risk factors and the novel kidney injury biomarkers for such prediction that we can predict CRS early and improve the risk reclassification in this disorder. ",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b23",
                    "text": "23"
                }
            ]
        },
        {
            "text": "Precisely, we will develop and validate a risk score that can identify patients with either a very high or a very low probability of developing AKI using only baseline characteristics and effective urine biomarkers before a detectable change in serum creatinine in ADHF patients."
        },
        {
            "text": "A total of 676 consecutive ADHF participants, aged 18 to 80 years, were prospectively enrolled between September 2011 and August 2014 from 6 regional central hospitals located in 5 cities in China. ",
            "section": "Methods Study Population and Database"
        },
        {
            "text": "All participants had given informed consent for this specific study. ",
            "section": "Methods Study Population and Database"
        },
        {
            "text": "Among these participants, 169 were excluded according to exclusion criteria ( Figure S1). ",
            "section": "Methods Study Population and Database",
            "ref_spans": [
                {
                    "start": 78,
                    "end": 87,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure S1"
                }
            ]
        },
        {
            "text": "The remaining 507 participants formed our study population, of which 321 participants from 4 of the 6 hospitals served as the development cohort to develop the risk score. ",
            "section": "Methods Study Population and Database"
        },
        {
            "text": "The remaining 186 participants from the other 2 hospitals served as independent validation cohort. ",
            "section": "Methods Study Population and Database"
        },
        {
            "text": "ADHF was diagnosed based on the European Society of Cardiology criteria. ",
            "section": "Methods Study Population and Database"
        },
        {
            "text": "24 Estimated glomerular filtration rate (eGRF) was determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. ",
            "section": "Methods Study Population and Database",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b24",
                    "text": "24"
                }
            ]
        },
        {
            "text": "25 All participants had consecutive measurements of serum creatinine and urine biomarkers every day during the first 7 days of hospitalization. ",
            "section": "Methods Study Population and Database",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b25",
                    "text": "25"
                }
            ]
        },
        {
            "text": "The values on the first day were used to develop the risk score for early prediction of AKI, and serum creatinine values on other days were used to assess the development of AKI.",
            "section": "Methods Study Population and Database"
        },
        {
            "text": "This research was approved by the Institutional Review Board of the Guangdong Provincial Institute of Nephrology and the ethics committees of the participating hospitals before recruiting patients.",
            "section": "Methods Study Population and Database"
        },
        {
            "text": "The primary outcome was the development of AKI. ",
            "section": "Outcome Definition"
        },
        {
            "text": "It was defined as an increase in serum creatinine by 26.5 lmol/L (0.3 mg/dL) within 48 hours of admission, or a 50% increase in serum creatinine from preadmission level (mean of at least 3 measurements over a 6-month period before admission) within 7 days of admission according to the KDIGO Clinical Practice Guidelines for Acute Kidney Injury. ",
            "section": "Outcome Definition"
        },
        {
            "text": "26 We did not use urine output criteria (ie, <0.5 mL/kg per hour for >6 hours) for AKI diagnosis because of lack of practicality in measurement when an indwelling urinary catheter was not present.",
            "section": "Outcome Definition",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b26",
                    "text": "26"
                }
            ]
        },
        {
            "text": "Sample size determination for observational study is difficult, especially in multiple regression model settings. ",
            "section": "Sample Size and Missing Data"
        },
        {
            "text": "We had used the rule of thumb recommended by Peduzzi et al 27 and Harrell et al, 28 namely, events per variable (EPV) being 10 or greater under this circumstance. ",
            "section": "Sample Size and Missing Data",
            "ref_spans": [
                {
                    "start": 59,
                    "end": 61,
                    "type": "bibr",
                    "ref_id": "b27",
                    "text": "27"
                },
                {
                    "start": 81,
                    "end": 83,
                    "type": "bibr",
                    "ref_id": "b28",
                    "text": "28"
                }
            ]
        },
        {
            "text": "We considered about 5 to 8 significant clinical factors and 2 to 3 biomarkers in developing a model. ",
            "section": "Sample Size and Missing Data"
        },
        {
            "text": "This would have required us to recruit a minimum of 110 (11910) participants who had events to predict the development of AKI.",
            "section": "Sample Size and Missing Data"
        },
        {
            "text": "There were 2 cases with incomplete measurements. ",
            "section": "Sample Size and Missing Data"
        },
        {
            "text": "We performed simple imputation for these 2 cases. ",
            "section": "Sample Size and Missing Data"
        },
        {
            "text": "One case with missing serum albumin was imputed by mean, and the other with missing N-terminal pro-B-type natriuretic peptide (NT-proBNP) by median because of skewness. ",
            "section": "Sample Size and Missing Data"
        },
        {
            "text": "All analyses were performed based on imputed complete cases.",
            "section": "Sample Size and Missing Data"
        },
        {
            "text": "We took 2 steps to develop the risk model based on the development cohort. ",
            "section": "Statistical Analysis"
        },
        {
            "text": "The first step was to select meaningful clinical risk factors (nonurine markers) by logistic regression with backward elimination. ",
            "section": "Statistical Analysis"
        },
        {
            "text": "Clinical candidate predictors significant at P<0.1 in univariate logistic regression models were considered for backward elimination. ",
            "section": "Statistical Analysis"
        },
        {
            "text": "In this step, a clinical model with clinical factors was developed. ",
            "section": "Statistical Analysis"
        },
        {
            "text": "Then, urine biomarkers (urine albumin-to-creatinine ratio [UACR], urinary NGAL [uNGAL], and uAGT) were evaluated sequentially based on this clinical model. ",
            "section": "Statistical Analysis",
            "ref_spans": [
                {
                    "start": 79,
                    "end": 86,
                    "type": "bibr",
                    "text": "[uNGAL]"
                }
            ]
        },
        {
            "text": "Category-free (continuous) net reclassification index (NRI), integrated discrimination improvement (IDI), 29 and added value of c statistics were used to quantify the additional contribution of these urine biomarkers to risk reclassification.",
            "section": "Statistical Analysis",
            "ref_spans": [
                {
                    "start": 106,
                    "end": 108,
                    "type": "bibr",
                    "ref_id": "b29",
                    "text": "29"
                }
            ]
        },
        {
            "text": "Predefined interactions (sex9preexisting chronic kidney disease [pre-CKD], pre-CKD9uNGAL, and pre-CKD9uAGT) between predictors and potential nonlinear association of included biomarkers were also examined at the 5% significance level. Sensitivity analysis was conducted to assess the influence of the 2 incomplete measures by leaving the corresponding 2 cases out. ",
            "section": "Statistical Analysis",
            "ref_spans": [
                {
                    "start": 81,
                    "end": 83,
                    "type": "bibr",
                    "ref_id": "b30",
                    "text": "30"
                },
                {
                    "start": 234,
                    "end": 236,
                    "type": "bibr",
                    "ref_id": "b31",
                    "text": "31"
                },
                {
                    "start": 304,
                    "end": 306,
                    "type": "bibr",
                    "ref_id": "b32",
                    "text": "32"
                }
            ]
        },
        {
            "text": "All analyses were done with SAS (SAS Institute Inc, Cary, NC, version 9.4). ",
            "section": "Statistical Analysis"
        },
        {
            "text": "A 2-sided P<0.05 was considered statistically significant.",
            "section": "Statistical Analysis"
        },
        {
            "text": "The reporting of the present study closely follows the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement. ",
            "section": "Statistical Analysis"
        },
        {
            "text": "33 Additional study methods are described in Data S1.",
            "section": "Statistical Analysis",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b33",
                    "text": "33"
                }
            ]
        },
        {
            "text": "The flow of participants is presented as Figure S1.  ",
            "section": "Results",
            "ref_spans": [
                {
                    "start": 41,
                    "end": 50,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure S1"
                }
            ]
        },
        {
            "text": "Table 1 shows the characteristics of eligible participants for both the development and validation cohort recorded on admission. ",
            "section": "Results",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 7,
                    "type": "table",
                    "ref_id": "tab_1",
                    "text": "Table 1"
                }
            ]
        },
        {
            "text": "The baseline characteristics of the validation cohort were generally similar to those of the development cohort, although the validation cohort was drawn from an independent group of participants. ",
            "section": "Results"
        },
        {
            "text": "Two cases with incomplete measurements were imputed as described in the Sample Size and Missing Data section. ",
            "section": "Results"
        },
        {
            "text": "Baseline characteristics outlining those who developed versus those who did not develop AKI were presented in Table S1.",
            "section": "Results",
            "ref_spans": [
                {
                    "start": 110,
                    "end": 118,
                    "type": "table",
                    "ref_id": "tab_1",
                    "text": "Table S1"
                }
            ]
        },
        {
            "text": "The clinical model, including age, sex, pre-CKD, serum albumin (ALB), and NT-proBNP (Table 2), had a c statistic of 0.767 (95% CI 0.714-0.820). ",
            "section": "Risk Score Development",
            "ref_spans": [
                {
                    "start": 84,
                    "end": 93,
                    "type": "table",
                    "ref_id": "tab_2",
                    "text": "(Table 2)"
                }
            ]
        },
        {
            "text": "The first urine biomarker added to the clinical model was uAGT, with a category-free NRI of 0.809 (P<0.001) and an IDI of 0.169 (P<0.001). ",
            "section": "Risk Score Development"
        },
        {
            "text": "The second urine biomarker added to the clinical model with uAGT was uNGAL, with a category-free NRI of 0.293 (P=0.012) and an IDI of 0.023 (P=0.011). ",
            "section": "Risk Score Development"
        },
        {
            "text": "However, UACR did not improve model prediction significantly, nor did it make an additional contribution to risk reclassification (Table S2). ",
            "section": "Risk Score Development",
            "ref_spans": [
                {
                    "start": 130,
                    "end": 140,
                    "type": "table",
                    "ref_id": "tab_2",
                    "text": "(Table S2)"
                }
            ]
        },
        {
            "text": "Thus, the risk model was obtained by adding uAGT and uNGAL rather than UACR to the clinical model. ",
            "section": "Risk Score Development"
        },
        {
            "text": "Neither nonlinearity nor interactions were found significant. ",
            "section": "Risk Score Development"
        },
        {
            "text": "The risk model has excellent discriminative power with a c statistic of 0.874 (95% CI 0.835-0.913), significantly larger than that of the clinical model (DeLong test, P<0.001).",
            "section": "Risk Score Development"
        },
        {
            "text": "Scores based on the risk model for all predictors are presented in Table 3. ",
            "section": "Risk Score Development",
            "ref_spans": [
                {
                    "start": 67,
                    "end": 74,
                    "type": "table",
                    "ref_id": "tab_3",
                    "text": "Table 3"
                }
            ]
        },
        {
            "text": "The estimated predicted probability of developing AKI during the first 7 days after admission for an individual ADHF patient according to the proposed risk score is expressed as p(AKI) \u00bc 1 1 \u00fe e \u00c0\u00f0\u00c04:027\u00fe0:115\u00c3totalriskscore\u00de",
            "section": "Risk Score Development"
        },
        {
            "text": "where \u00c04.027 and 0.115 are the intercept and slope coefficients of the regression, respectively. ",
            "section": "Risk Score Development"
        },
        {
            "text": "The total risk score ranges from a minimum value of 0 (lowest risk) to a maximum value of 55 (highest risk), with corresponding estimated predicted probabilities of developing AKI ranging from 1.8% to 90.9% (Table S3). ",
            "section": "Risk Score Development",
            "ref_spans": [
                {
                    "start": 207,
                    "end": 216,
                    "type": "table",
                    "ref_id": "tab_3",
                    "text": "(Table S3"
                }
            ]
        },
        {
            "text": "The optimism-corrected c statistic of the risk score in the development cohort, by the bootstrapping technique, was 0.859.",
            "section": "Risk Score Development"
        },
        {
            "text": "To illustrate the application of the risk score, consider a 60-year-old woman with ADHF, preexisting CKD, ALB of 40 g/ L, NT-proBNP of 3200 pg/mL, uNGAL of 65 lg/g Cr, and uAGT of 35 lg/g Cr. ",
            "section": "Risk Score Development"
        },
        {
            "text": "The total risk score she gets is 0+2+9+0+0+6+13=30 from Table 3, and the estimated predicted probability that she will develop AKI is 36.0% according to Table S3. ",
            "section": "Risk Score Development",
            "ref_spans": [
                {
                    "start": 56,
                    "end": 63,
                    "type": "table",
                    "ref_id": "tab_3",
                    "text": "Table 3"
                },
                {
                    "start": 153,
                    "end": 161,
                    "type": "table",
                    "ref_id": "tab_3",
                    "text": "Table S3"
                }
            ]
        },
        {
            "text": "An easy-to-use online tool (http:// www.echobelt.org/risk/) as well as an Excel tool was developed whereby an individual's underlying risk of AKI can be estimated by entering the individual's own characteristics.",
            "section": "Risk Score Development"
        },
        {
            "text": "In an independent validation cohort, the c statistics of the developed risk score was 0.847 (95% CI 0.795-0.910). ",
            "section": "Validation of Risk Score"
        },
        {
            "text": "The receiver operating characteristics curves (ROCs) of the clinical model, the risk model, the risk score, and models with only uNGAL or uAGT are shown in Figure 1. ",
            "section": "Validation of Risk Score",
            "ref_spans": [
                {
                    "start": 156,
                    "end": 164,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1"
                }
            ]
        },
        {
            "text": "The calibration plots for both cohorts show the close agreement between predicted and observed risk of AKI, with no apparent over-or underprediction ( Figure 2). ",
            "section": "Validation of Risk Score",
            "ref_spans": [
                {
                    "start": 151,
                    "end": 159,
                    "type": "figure",
                    "ref_id": "fig_1",
                    "text": "Figure 2"
                }
            ]
        },
        {
            "text": "AKI rates from both development and validation cohorts are also concordant with each other.",
            "section": "Validation of Risk Score"
        },
        {
            "text": "We divided the risk scores into 4 groups, that is, low risk (0-24 points), moderate risk (25-34 points), high risk (35-44 points), and very high risk (45-55 points) ( Figure 3), according to the quartiles of estimated risk, to enhance the clinical utility of the risk score. ",
            "section": "Clinical Implications of the Risk Score",
            "ref_spans": [
                {
                    "start": 115,
                    "end": 129,
                    "type": "bibr",
                    "text": "(35-44 points)"
                },
                {
                    "start": 167,
                    "end": 175,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "Figure 3"
                }
            ]
        },
        {
            "text": "In the development and validation cohorts AKI was  Figure 3 shows, the risk of developing AKI is highly and positively associated with the risk scores (Pearson contingency coefficient=0.517, P for trend <0.001). ",
            "section": "Clinical Implications of the Risk Score",
            "ref_spans": [
                {
                    "start": 51,
                    "end": 59,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "Figure 3"
                }
            ]
        },
        {
            "text": "We also performed subgroup analysis according to LVEF. ",
            "section": "Clinical Implications of the Risk Score"
        },
        {
            "text": "The c statistics of the risk score for participants with LVEF <45% and \u226545% are 0.849 (95% CI 0.786-0.912) and 0.870 (95% CI 0.811-0.928), respectively. ",
            "section": "Clinical Implications of the Risk Score"
        },
        {
            "text": "The discrimination power of 2 subgroups was similar, suggesting that the risk score was applicable for both subgroups of participants. ",
            "section": "Clinical Implications of the Risk Score"
        },
        {
            "text": "The generated risk score was also correlated with the presence and stage of AKI. ",
            "section": "Clinical Implications of the Risk Score"
        },
        {
            "text": "The score was significantly higher in those patients who developed AKI than those who did not. ",
            "section": "Clinical Implications of the Risk Score"
        },
        {
            "text": "Higher risk score was observed in patients with higher stage of AKI (Spearman rank correlation coefficient, r=0.59, P<0.001, Figure S2). ",
            "section": "Clinical Implications of the Risk Score",
            "ref_spans": [
                {
                    "start": 125,
                    "end": 134,
                    "type": "figure",
                    "ref_id": "fig_1",
                    "text": "Figure S2"
                }
            ]
        },
        {
            "text": "In addition, the discriminatory ability of the score for predicting death was also good, with a c statistic of 0.815 (95% CI 0.762-0.867) ( Figure S3). ",
            "section": "Clinical Implications of the Risk Score",
            "ref_spans": [
                {
                    "start": 140,
                    "end": 149,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "Figure S3"
                }
            ]
        },
        {
            "text": "Furthermore, we also developed a clinical score based on the clinical model with prognostic factors presented in Table 2. ",
            "section": "Clinical Implications of the Risk Score",
            "ref_spans": [
                {
                    "start": 113,
                    "end": 120,
                    "type": "table",
                    "ref_id": "tab_2",
                    "text": "Table 2"
                }
            ]
        },
        {
            "text": "The clinical score had an acceptable c statistic of 0.729 (95% CI 0.672-0.786). ",
            "section": "Clinical Implications of the Risk Score"
        },
        {
            "text": "Validation of the clinical score was performed on the development data set with bootstrap internal validation and the validation data set as external validation, with c statistic of 0.730 (95% CI 0.673-0.786) and 0.742 (95% CI 0.666-0.818), respectively. ",
            "section": "Clinical Implications of the Risk Score"
        },
        {
            "text": "Risk score for each variable is given in Table S4. ",
            "section": "Clinical Implications of the Risk Score",
            "ref_spans": [
                {
                    "start": 41,
                    "end": 49,
                    "type": "table",
                    "text": "Table S4"
                }
            ]
        },
        {
            "text": "The ROCs and calibration plots, as well as risk categories, are presented in Figures S4 through S6.",
            "section": "Clinical Implications of the Risk Score"
        },
        {
            "text": "First, to assess the influence of the 2 incomplete measures, we derived a risk model on a complete data set by leaving the corresponding 2 cases out. ",
            "section": "Sensitivity Analysis"
        },
        {
            "text": "The discrimination power (c statistic 0.873, 95% CI 0.834-0.912) was almost the same as that from imputed complete cases. ",
            "section": "Sensitivity Analysis"
        },
        {
            "text": "Further, applying the risk score to all participants yielded a c statistic of 0.855 (95% CI 0.820-0.890), which was similar to that from the development cohort, suggesting high stability of the risk score. ",
            "section": "Sensitivity Analysis"
        },
        {
            "text": "We also conducted sensitivity analysis to assess the single biomarker discriminative power by adding a single biomarker to the clinical model. ",
            "section": "Sensitivity Analysis"
        },
        {
            "text": "The results are presented in Table S5. ",
            "section": "Sensitivity Analysis",
            "ref_spans": [
                {
                    "start": 29,
                    "end": 37,
                    "type": "table",
                    "ref_id": "tab_6",
                    "text": "Table S5"
                }
            ]
        },
        {
            "text": "Briefly, the final risk model had the lowest AIC and highest c statistic in the development data set. ",
            "section": "Sensitivity Analysis"
        },
        {
            "text": "Furthermore, because of the correlation between pre-CKD and eGFR, eGFR was not selected during the backward selection. ",
            "section": "Sensitivity Analysis"
        },
        {
            "text": "Thus, we kept the final risk model with pre-CKD.",
            "section": "Sensitivity Analysis"
        },
        {
            "text": "We have developed and validated a clinical scoring system to identify patients at a very high as well as a very low risk of   developing AKI before a detectable change in serum creatinine in ADHF patients. ",
            "section": "Main Finding"
        },
        {
            "text": "The risk score was derived from a risk model including 5 clinical factors and 2 urine biomarkers. ",
            "section": "Main Finding"
        },
        {
            "text": "The clinical risk factors in the model were similar to those in previous reports. ",
            "section": "Main Finding"
        },
        {
            "text": "34,35 Two selected biomarkers, uAGT and uNGAL, were highly predictive. ",
            "section": "Main Finding",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b34",
                    "text": "34,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b35",
                    "text": "35"
                }
            ]
        },
        {
            "text": "The proposed risk score shows high discriminant power (optimism-corrected c statistic of 0.859) and is strongly supported by external validation (c statistics of 0.847). ",
            "section": "Main Finding"
        },
        {
            "text": "To our knowledge, this is the first clinical scoring system derived and validated for early prediction of AKI in ADHF patients incorporating clinical risk factors and novel kidney injury biomarkers.",
            "section": "Main Finding"
        },
        {
            "text": "Coexistence of ADHF and AKI, namely acute CRS, is a serious clinical condition associated with significantly increased morbidity and mortality in patients with heart failure. ",
            "section": "Need for Early Predicting AKI in ADHF"
        },
        {
            "text": "10,36 A major barrier to improving clinical outcomes in ADHF patients is the lack of ability to identify patients at high-risk of CRS early enough to initiate interventions. ",
            "section": "Need for Early Predicting AKI in ADHF",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "10,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b36",
                    "text": "36"
                }
            ]
        },
        {
            "text": "37 The clinical benefits of an early diagnosis of AKI have not been fully realized due to the restriction of using serum creatinine for diagnosis. ",
            "section": "Need for Early Predicting AKI in ADHF",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b37",
                    "text": "37"
                }
            ]
        },
        {
            "text": "This restriction often leads to diagnostic delays and potential misclassification of actual injury status and provides little information regarding underlying cause. ",
            "section": "Need for Early Predicting AKI in ADHF"
        },
        {
            "text": "Actually, all successful therapeutic approaches in animal models used in patients have yielded disappointing results. ",
            "section": "Need for Early Predicting AKI in ADHF"
        },
        {
            "text": "38 Major reasons are the scarcity of early biomarkers for AKI and consequent unacceptable delay in initiating treatment regimens. ",
            "section": "Need for Early Predicting AKI in ADHF",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b38",
                    "text": "38"
                }
            ]
        },
        {
            "text": "15 AKI is a major contributor to poor patient outcomes. ",
            "section": "Need for Early Predicting AKI in ADHF",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b15",
                    "text": "15"
                }
            ]
        },
        {
            "text": "The International Society of Nephrology (ISN)'s 0by25 (zero preventable deaths by 2025) initiative aims to eliminate preventable deaths from AKI by 2025 by calling for global strategies that permit timely diagnosis and treatment of potentially reversible AKI. ",
            "section": "Need for Early Predicting AKI in ADHF"
        },
        {
            "text": "39 As Mehta et al addressed in the Future Perspective Section, \"the effect of AKI on morbidity and mortality will be shaped by advances in methods to detect AKI earlier in the disease course.\" 39 Because early detection of AKI is helpful in identifying early kidney injury and preventing the progression of the kidney damage, our work may provide the first step forward to avoid harm to the kidney and devise early preventive strategies in CRS.",
            "section": "Need for Early Predicting AKI in ADHF",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b39",
                    "text": "39"
                },
                {
                    "start": 193,
                    "end": 195,
                    "type": "bibr",
                    "ref_id": "b39",
                    "text": "39"
                }
            ]
        },
        {
            "text": "The present study derived and validated a potential clinical prediction tool rather than a decision rule. ",
            "section": "Clinical and Policy Implications"
        },
        {
            "text": "It is to aid the attending physician who will make the clinical decision. ",
            "section": "Clinical and Policy Implications"
        },
        {
            "text": "The factors incorporated in the proposed risk score are readily available data recorded on admission or from routine medical examination. ",
            "section": "Clinical and Policy Implications"
        },
        {
            "text": "Both uAGT and uNGAL are accepted and utilized biomarkers of kidney injury. ",
            "section": "Clinical and Policy Implications"
        },
        {
            "text": "To date, clinical studies that use the biomarkers to predict acute CRS yield only modest performance in general. ",
            "section": "Clinical and Policy Implications"
        },
        {
            "text": "40,41 Individual prediction of AKI remains a challenge in the setting of ADHF. ",
            "section": "Clinical and Policy Implications",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b40",
                    "text": "40,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b41",
                    "text": "41"
                }
            ]
        },
        {
            "text": "Therefore, stratification of risk level according to the score incorporating both clinical factors and biomarkers is clinically relevant, particularly in critically ill patients with multiorgan dysfunctions.",
            "section": "Clinical and Policy Implications"
        },
        {
            "text": "NGAL is a novel biomarker widely utilized to identify AKI patients and detect patients with likely subclinical AKI who have an increased risk of adverse outcomes. ",
            "section": "Comparison With NGAL and Other Risk Score"
        },
        {
            "text": "42 A systematic review and meta-analysis 43 demonstrated that the overall c statistic of NGAL to predict AKI is 0.815. ",
            "section": "Comparison With NGAL and Other Risk Score",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b42",
                    "text": "42"
                },
                {
                    "start": 41,
                    "end": 43,
                    "type": "bibr",
                    "ref_id": "b43",
                    "text": "43"
                }
            ]
        },
        {
            "text": "This meta-analysis synthesized data from different settings and varied study populations, such as contrast-induced nephropathy, cardiac surgery-associated acute kidney injury. ",
            "section": "Comparison With NGAL and Other Risk Score"
        },
        {
            "text": "The c statistics of NGAL reported from individual study were less than 0.74, except for 1 study with the c statistic of 0.93, 13 the study population of which was a subgroup of children with an extremely high cutoff point (170 ng/L) and relative small sample size of 119. ",
            "section": "Comparison With NGAL and Other Risk Score",
            "ref_spans": [
                {
                    "start": 126,
                    "end": 128,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "13"
                }
            ]
        },
        {
            "text": "In contrast, our study has included 507 ADHF adult patients, and the c statistic of NGAL alone as a predictor is only 0.761, much less than that of our risk model (c statistic of 0.874) and risk score (c statistic of 0.859).",
            "section": "Comparison With NGAL and Other Risk Score"
        },
        {
            "text": "Thakar et al 44 reported a risk score using clinical parameters from patients receiving open-heart surgery and yielded an excellent c statistic of 0.81 (95% CI 0.78-0.83). ",
            "section": "Comparison With NGAL and Other Risk Score",
            "ref_spans": [
                {
                    "start": 13,
                    "end": 15,
                    "type": "bibr",
                    "ref_id": "b44",
                    "text": "44"
                }
            ]
        },
        {
            "text": "Our score was developed in a cohort of ADHF patients whose clinical characteristics and risk exposure were different from those of the patients with heart surgery. ",
            "section": "Comparison With NGAL and Other Risk Score"
        },
        {
            "text": "The c statistic of the proposed score for predicting acute CRS reached 0.859, demonstrating excellent performance of our risk score in ADHF patients.",
            "section": "Comparison With NGAL and Other Risk Score"
        },
        {
            "text": "Sensitivity analysis showed that the 2 incomplete measures had little influence on the risk model. ",
            "section": "Comparison With NGAL and Other Risk Score"
        },
        {
            "text": "Furthermore, we have kept age, sex, NT-proBNP, and serum albumin in the final risk model, although they were not statistically significant. ",
            "section": "Comparison With NGAL and Other Risk Score"
        },
        {
            "text": "Age and sex were given factors for controlling potential patients' heterogeneity. ",
            "section": "Comparison With NGAL and Other Risk Score"
        },
        {
            "text": "NT-proBNP and serum albumin were also found significantly associated with the development of AKI in univariate analysis and by other researchers. ",
            "section": "Comparison With NGAL and Other Risk Score"
        },
        {
            "text": "45,46 We also developed a clinical score that reached acceptable performance. ",
            "section": "Comparison With NGAL and Other Risk Score",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b45",
                    "text": "45,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b46",
                    "text": "46"
                }
            ]
        },
        {
            "text": "Clinicians could choose the one that fits their clinical practice best.",
            "section": "Comparison With NGAL and Other Risk Score"
        },
        {
            "text": "Our study has several strengths. ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "First, our risk score was derived for early detection of patients at high risk of developing AKI incorporating, for the first time, both baseline characteristics and novel biomarkers recorded on the first day of admission before a clinically significant change in serum creatinine. ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "Second, the risk score possesses high discriminative power as well as high stability and reproducibility, as shown by concordance between internal and external validation. ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "Third, to develop a prediction tool for early detection of patients who would develop AKI during hospitalization, researchers should exclude those who already have AKI on admission. ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "In our study we excluded those having AKI on admission based on preadmission measurements of serum creatinine, but we did not use this information in developing the risk score; thus, the use of the developed predicting tool is not limited by the need for preadmission serum creatinine. ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "Last, our article closely follows the TRIPOD statement.",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "The study also has limitations. ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "First, AKI diagnosed by an increase in serum creatinine may introduce the dilemma of using a surrogate outcome to assess the performance of novel models. ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "47 Evidence of AKI on renal biopsy would be the gold standard but was not feasible in our large cohort. ",
            "section": "Strengths and Limitations of This Study",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b47",
                    "text": "47"
                }
            ]
        },
        {
            "text": "As is the case in most AKI studies, we did not use urine output criteria (ie, <0.5 mL/kg per hour for >6 hours) for AKI diagnosis because urine output as the diagnostic criterion for AKI has been questioned recently for its limited sensitivity when diuretics are administered, reduced specificity in the presence of dehydration, and lack of practicality when an indwelling urinary catheter is not present (as in our setting). ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "15 Second, our findings remain to be confirmed by other independent studies. ",
            "section": "Strengths and Limitations of This Study",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b15",
                    "text": "15"
                }
            ]
        },
        {
            "text": "The question of whether the model predicts AKI in the special setting of ADHF versus AKI from other causes remains to be addressed. ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "Third, although the study participants were recruited from 6 hospitals located in 5 cities in China, generalizability of the risk score to other populations still needs to be validated. ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "In addition, the bootstrap procedure to estimate the overoptimism was conducted based on the developed risk score, which did not include the model selection step. ",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "The estimate of the overoptimism could be substantially biased under this circumstance.",
            "section": "Strengths and Limitations of This Study"
        },
        {
            "text": "We developed and validated a novel risk score by incorporating both major clinical risk factors and effective urine biomarkers to predict AKI in ADHF patients early. ",
            "section": "Conclusions"
        },
        {
            "text": "Individual risk prediction, as well as risk stratification based on the risk score, may assist clinicians to assess the risk of AKI in ADHF patients, which, in turn, would help them to plan and initiate the most appropriate disease management for patients in time.",
            "section": "Conclusions"
        },
        {
            "text": "Data S1.",
            "section": "Conclusions"
        },
        {
            "text": "Study Design. ",
            "section": "Supplemental Methods"
        },
        {
            "text": "The study is a prospective, multi-center, observational study. ",
            "section": "Supplemental Methods"
        },
        {
            "text": "All patients provided informed written consent for the procedure(s) and the study was approved by the Institutional Review Board. ",
            "section": "Supplemental Methods"
        },
        {
            "text": "The inclusion criteria were patients with ADHF ",
            "section": "Supplemental Methods"
        },
        {
            "text": "1) who were admitted to the six participating hospitals, and ",
            "section": "Supplemental Methods"
        },
        {
            "text": "2) who had at least three measurements of serum creatinine over a six-month period before admission. ",
            "section": "Supplemental Methods"
        },
        {
            "text": "Exclusion criteria were ",
            "section": "Supplemental Methods"
        },
        {
            "text": "1) exposing to nephrotoxins, such as contrast media, aminoglycoside antibiotics, vancomycin, and/or non-steroidal anti-inflammatory drugs except aspirin, within 4 weeks before admission or during hospital stay, ",
            "section": "Supplemental Methods"
        },
        {
            "text": "2) pre-existing advanced chronic kidney disease (CKD) (chronic dialysis or pre-admission estimated glomerular filtration rate [Egfr] <30 ml/min/1\u202273m 2 ), ",
            "section": "Supplemental Methods"
        },
        {
            "text": "3) urinary tract infection or obstruction, cancer, a concurrent diagnosis of an acute coronary syndrome, cardiogenic shock or need for inotropes, ",
            "section": "Supplemental Methods"
        },
        {
            "text": "4) heart failure following cardiac surgery, and ",
            "section": "Supplemental Methods"
        },
        {
            "text": "5) having AKI on admission (i.e., those with a 50% increase in serum creatinine from preadmission level on the day of hospitalization).",
            "section": "Supplemental Methods"
        },
        {
            "text": "Urine and blood samples were measured in a central laboratory with standard protocol. ",
            "section": "Laboratory measurements"
        },
        {
            "text": "A sandwich ELISA kit (Immuno-Biologic Laboratories Co. Ltd, Japan) was used for quantifying AGT in urine, and further confirmed by western blot analyses. ",
            "section": "Laboratory measurements"
        },
        {
            "text": "uNGAL was measured with an ELISA kit (Antibody Shop, Denmark). ",
            "section": "Laboratory measurements"
        },
        {
            "text": "Urine albumin to creatinine ratio (UACR) was measured using an automatic analyzer (Siemens BNPro Spec, Germany). ",
            "section": "Laboratory measurements"
        },
        {
            "text": "All urine biomarkers were normalized based on the level of urinary creatinine. ",
            "section": "Laboratory measurements"
        },
        {
            "text": "Estimated glomerular filtration rate (GRF) was determined by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (1).",
            "section": "Laboratory measurements",
            "ref_spans": [
                {
                    "start": 130,
                    "end": 133,
                    "type": "bibr",
                    "text": "(1)"
                }
            ]
        },
        {
            "text": "Candidate predictors included clinical variables such as sex, age (years), hypertension, diabetes mellitus, pre-existing CKD indicated from medical records, or reported by patients, or diagnosed by doctor, prior hospitalization for heart failure, left ventricular ejection fraction, severity of breathlessness by the New York Heart Association (NYHA) classification, NT-proBNP (pg/ml), systolic and diastolic blood pressure (mmHg), serum albumin (g/L), serum creatinine (\u03bcmol/L), hemoglobin (g/L), use of renin-angiotensin system blockersand/or diuretic, and urine biomarkers such as urine albumin to creatinine ratio (UACR, mg/g Cr), uNGAL (\u03bcg/g Cr) and uAGT (\u03bcg/g Cr). ",
            "section": "Candidate predictors"
        },
        {
            "text": "All these variables were assessed and recorded on admission.",
            "section": "Candidate predictors"
        },
        {
            "text": "We took two steps to develop a risk model based on the development cohort. ",
            "section": "Statistical analysis"
        },
        {
            "text": "The first was to select meaningful clinical risk factors (non-urine markers) by logistic regression with backward elimination. ",
            "section": "Statistical analysis"
        },
        {
            "text": "Clinical candidate predictors significant at P<0.1 in univariate logistic regression models were considered for backward elimination. ",
            "section": "Statistical analysis"
        },
        {
            "text": "In this step, a clinical model with clinical factors was developed. ",
            "section": "Statistical analysis"
        },
        {
            "text": "Then, urine biomarkers (UACR, uNGAL and uAGT)",
            "section": "Statistical analysis"
        },
        {
            "text": "were evaluated sequentially based on this clinical model. ",
            "section": "Statistical analysis"
        },
        {
            "text": "The likelihood ratio \u03c7 2 test (2) was used to evaluate the significance of the added urine biomarkers, and net-reclassification index (NRI) and integrated discrimination improvement (IDI) (3) were used to quantify the additional contribution of these urine biomarkers to risk reclassification.",
            "section": "Statistical analysis"
        },
        {
            "text": "To develop the risk score, the scoring method similar to Sullivan et al's (4)  The natural logarithmic transformation of NT-proBNP and all urine biomarkers was made because of their extreme positive skewness. ",
            "section": "Statistical analysis",
            "ref_spans": [
                {
                    "start": 74,
                    "end": 77,
                    "type": "bibr",
                    "text": "(4)"
                }
            ]
        },
        {
            "text": "Generalized additive model (GAM) (8) was used to explore the potential nonlinear relationship between those continuous variables and the outcome. ",
            "section": "Statistical analysis",
            "ref_spans": [
                {
                    "start": 33,
                    "end": 36,
                    "type": "bibr",
                    "text": "(8)"
                }
            ]
        },
        {
            "text": "The clinical meaningful interactions between predictors were also examined. ",
            "section": "Statistical analysis"
        },
        {
            "text": "Continuous variables were expressed as mean (SD) or median (1 st Quarter-3 rd Quarter). ",
            "section": "Statistical analysis"
        },
        {
            "text": "Categorical variables were expressed as percentages. ",
            "section": "Statistical analysis"
        },
        {
            "text": "Sensitivity analysis was conducted to assess the influence of the two incomplete measures by leaving the corresponding two cases out. ",
            "section": "Statistical analysis"
        },
        {
            "text": "Further, we also applied the risk score to the whole participants as sensitivity analysis. ",
            "section": "Statistical analysis"
        },
        {
            "text": "All analyses were done with SAS (SAS Institute Inc., Cary, NC, version 9.4). ",
            "section": "Statistical analysis"
        },
        {
            "text": "A two-sided P<0.05 was considered statistically significant.  ",
            "section": "Statistical analysis"
        },
        {
            "text": "21.0(5.7-51.4) 162.7(56.0-393.6) <.001 ",
            "section": "Statistical analysis",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b21",
                    "text": "21"
                }
            ]
        },
        {
            "text": "Abbreviations: IQR, interquartile Range; AKI, Acute Kidney Injury; pre-CKD, pre-existing chronic kidney disease; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; UACR, urine albumin to creatinine ratio. ",
            "section": "Statistical analysis"
        },
        {
            "text": "uNGAL, urinary neutrophil gelatinase-associated lipocalin; uAGT, urinary angiotensionogen. ",
            "section": "Statistical analysis"
        },
        {
            "text": "* Defined as pre-admission eGFR<60ml/min/1.73m2. ",
            "section": "Statistical analysis"
        },
        {
            "text": "Pre-admission eGFR=the mean of at least three measurements over a six-month period before admission   Figure S1. ",
            "section": "Statistical analysis",
            "ref_spans": [
                {
                    "start": 102,
                    "end": 111,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure S1"
                }
            ]
        },
        {
            "text": "Flow of enrollment of the study participants. ",
            "section": "Statistical analysis"
        },
        {
            "text": "Figure S2. ",
            "section": "Statistical analysis",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 9,
                    "type": "figure",
                    "ref_id": "fig_1",
                    "text": "Figure S2"
                }
            ]
        },
        {
            "text": "Boxplot showing the risk score across different AKI stage of the patients. ",
            "section": "Statistical analysis"
        },
        {
            "text": "Significant difference in average risk score of different AKI stage was found, with higher risk score in patients with higher stage of AKI (P value by one-way ANOVA analysis, <0.001).    ",
            "section": "Statistical analysis"
        },
        {
            "text": "Risks were categorized into low-risk (0-4 points), moderate-risk (5-9 points), high-risk (10-14 points), very high-risk (15-18 points). ",
            "section": "Statistical analysis"
        },
        {
            "text": "Higher points means higher risk of developing AKI in patients with ADHF, P for trend<0.001.",
            "section": "Statistical analysis"
        },
        {
            "text": "Supplemental risk calculator AKI risk calculator.",
            "section": "Statistical analysis"
        },
        {
            "text": "The authors have followed the STROBE checklist in collecting and reporting their data and the TRIPOD checklist in reporting the prediction model. ",
            "section": "Acknowledgments"
        },
        {
            "text": "Elements of the checklist are incorporated into the manuscript. ",
            "section": "Acknowledgments"
        },
        {
            "text": "Further details of any particular checklist item are available on request from the corresponding authors.",
            "section": "Acknowledgments"
        },
        {
            "text": "This study was supported by the National Natural Science Foundation of China (no. 81273191/81673270) granted to Prof Chen and the National Natural Science Foundation of China (no. 81430016) to Dr Hou.",
            "section": "Sources of Funding"
        },
        {
            "text": "None.",
            "section": "Disclosures"
        }
    ]
}